U.S. flag

An official website of the United States government

NM_000203.5(IDUA):c.326_331del (p.Tyr109_Asn110del) AND Mucopolysaccharidosis type 1

Germline classification:
Pathogenic/Likely pathogenic (2 submissions)
Last evaluated:
Nov 28, 2023
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003051157.4

Allele description [Variation Report for NM_000203.5(IDUA):c.326_331del (p.Tyr109_Asn110del)]

NM_000203.5(IDUA):c.326_331del (p.Tyr109_Asn110del)

Gene:
IDUA:alpha-L-iduronidase [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
4p16.3
Genomic location:
Preferred name:
NM_000203.5(IDUA):c.326_331del (p.Tyr109_Asn110del)
HGVS:
  • NC_000004.12:g.1000638_1000643del
  • NG_008103.1:g.18642_18647del
  • NM_000203.4:c.326_331delACAACT
  • NM_000203.5:c.326_331delMANE SELECT
  • NM_001363576.1:c.-71_-66del
  • NP_000194.2:p.Tyr109_Asn110del
  • LRG_1277t1:c.326_331del
  • LRG_1277:g.18642_18647del
  • LRG_1277p1:p.Tyr109_Asn110del
  • NC_000004.11:g.994424_994429del
  • NC_000004.11:g.994426_994431del
  • NM_000203.5:c.326_331del
  • NR_110313.1:n.414_419del
Molecular consequence:
  • NM_001363576.1:c.-71_-66del - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_000203.5:c.326_331del - inframe_deletion - [Sequence Ontology: SO:0001822]
  • NR_110313.1:n.414_419del - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:
Mucopolysaccharidosis type 1
Synonyms:
Mucopolysaccharidosis type I; MPS 1; Attenuated MPS I (subtype); See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0001586; MedGen: C0023786

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003450274Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Nov 28, 2023)
germlineclinical testing

PubMed (2)
[See all records that cite these PMIDs]

SCV003934352Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Likely pathogenic
(May 1, 2023)
germlineclinical testing

PubMed (4)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group, Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Insights into mucopolysaccharidosis I from the structure and action of α-L-iduronidase.

Bie H, Yin J, He X, Kermode AR, Goddard-Borger ED, Withers SG, James MN.

Nat Chem Biol. 2013 Nov;9(11):739-45. doi: 10.1038/nchembio.1357. Epub 2013 Sep 11. Erratum in: Nat Chem Biol. 2013 Nov;9(11):746.

PubMed [citation]
PMID:
24036510
PMCID:
PMC4954775
See all PubMed Citations (5)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV003450274.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (2)

Description

This variant, c.326_331del, results in the deletion of 2 amino acid(s) of the IDUA protein (p.Tyr109_Asn110del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (no rsID available, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with IDUA-related conditions. ClinVar contains an entry for this variant (Variation ID: 2142765). This variant disrupts a region of the IDUA protein in which other variant(s) (p.Tyr109His) have been determined to be pathogenic (PMID: 31386236). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV003934352.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (4)

Description

Variant summary: IDUA c.326_331delACAACT (p.Tyr109_Asn110del) results in an in-frame deletion that is predicted to remove 2 amino acids from the encoded protein. The variant allele was found at a frequency of 4e-06 in 250358 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.326_331delACAACT in individuals affected with Mucopolysaccharidosis Type 1 and no experimental evidence demonstrating its impact on protein function have been reported. However, missense variants affecting the residues that are deleted by this variant have been reported in Mucopolysaccharidosis Type 1 patients in the literature; i.e. in 5 homozygotes with Y109H, who had intermediate (Hurler-Scheie syndrome) phenotype (Taghikhani_2019), and 2 in compound heterozygous patients with the N110D/Q70X genotype, who had severe (Hurler syndrome) phenotype (Clarke_2019). These reports suggest that other variants altering these residues might be also associated with disease. In addition, the N110 residue, was reported as a protein glycosylation site (e.g. Maita_2013, Bie_2013). The following publications have been ascertained in the context of this evaluation (PMID: 31386236, 31194252, 23959878 , 24036510). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014, and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 18, 2024